Using Llama-VHH to optimize T-cell mediated immunotherapies
The potential of T-cell engaging VHH single-domain therapeutics
This webinar summarised the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and showed how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.
In this webcast, speakers introduced the unique benefits of the VHH antibodies generated from the hLlamdA™ synthetic library and summarized how single domain VHH antibodies can be engineered to tune their binding selectivity and specificity for antigen targeting and be applied to optimize the next generation of these important new therapeutic modalities.
- What are VHHs?
- What is the clinical and research landscape for CAR-T and T-cell engagers?
- Means by which the shortfalls of current CAR-T and T-cell engaging therapies can be overcome through the incorporation of VHH